Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · IEX Real-Time Price · USD
0.680
+0.010 (1.46%)
Apr 25, 2024, 9:57 AM EDT - Market open
Company Description
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases.
The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021.
Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Chemomab Therapeutics Ltd.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Dr. Adi Mor George Ph.D. |
Contact Details
Address: Kiryat Atidim, Building 7 Tel Aviv, L3 6158002 Israel | |
| Phone | 972-77-331-0156 |
| Website | chemomab.com |
Stock Details
| Ticker Symbol | CMMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001534248 |
| CUSIP Number | 03280X102 |
| ISIN Number | US16385C1045 |
| Employer ID | 81-3676773 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, Chief Executive Officer and Executive Director |
| Sigal Fattal CPA, M.B.A. | Chief Financial Officer |
| Dr. Matthew B. Frankel M.B.A., M.D. | Chief Medical Officer and Vice President of Drug Development |
| Barbara Lindheim | Consulting Vice President of Investor and Public Relations, Strategic Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 11, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 7, 2024 | 6-K | Report of foreign issuer |
| Jan 3, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 9, 2023 | 6-K | Report of foreign issuer |
| Nov 3, 2023 | EFFECT | Notice of Effectiveness |
| Oct 30, 2023 | F-3/A | Filing |
| Oct 16, 2023 | F-3 | Filing |
| Aug 14, 2023 | 6-K | Report of foreign issuer |